Shares of Endo Pharmaceuticals (NASDAQ: ENDP) are lower on the session by 1.39%, trading at $33.98.

Overall call volume is now running at 14.67x the daily average, with 40% of all calls traded being purchases on the offer. 4,049 contracts have traded on the session so far.

Endo Pharmaceuticals Holdings Inc. is a specialty pharmaceutical company in pain management. The company is engaged in the research, development, manufacturing, marketing and sales of branded and generic pharmaceutical products used primarily to treat and manage pain, overactive bladder, prostate and bladder cancer and central precocious puberty.